journal article·2024-05-29Open access

3D Bioprinted Tumor-Stroma Models of Triple-Negative Breast Cancer Stem Cells for Preclinical Targeted Therapy Evaluation

Patricia González-Callejo, Clara García-Astrain, Ada Herrero-Ruiz, Malou Henriksen-Lacey, Joaquín Seras-Franzoso, Ibane Abasolo, Luis M. Liz-Marzán

ACS Applied Materials & Interfaces· Volume 16· Issue 21

Abstract

High Resolution Image Download MS PowerPoint Slide Breast cancer stem cells (CSCs) play a pivotal role in therapy resistance and tumor relapse, emphasizing the need for reliable in vitro models that recapitulate the complexity of the CSC tumor microenvironment to accelerate drug discovery. We present a bioprinted breast CSC tumor-stroma model incorporating triple-negative breast CSCs (TNB-CSCs) and stromal cells (human breast fibroblasts), within a breast-derived decellularized extracellular matrix bioink. Comparison of molecular signatures in this model with different clinical subtypes of bioprinted tumor-stroma models unveils a unique molecular profile for artificial CSC tumor models. We additionally demonstrate that the model can recapitulate the invasive potential of TNB-CSC. Surface-enhanced Raman scattering imaging allowed us to monitor the invasive potential of tumor cells in deep z -axis planes, thereby overcoming the depth-imaging limitations of confocal fluorescence microscopy. As a proof-of-concept application, we conducted high-throughput drug testing analysis to assess the efficacy of CSC-targeted therapy in combination with conventional chemotherapeutic compounds. The results highlight the usefulness of tumor-stroma models as a promising drug-screening platform, providing insights into therapeutic efficacy against CSC populations resistant to conventional therapies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Cancer Cells and Metastasis · Cellular Mechanics and Interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián 20014, Spain

Centro de Investigación Biomédica en Red, Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 20014 Donostia-San Sebastián, Barcelona 08035, Spain

Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d’Hebron Research Institute (VHIR), Vall d’Hebron University Hospital, Barcelona 08035, Spain

Department of Genetics and Microbiology, Universitat Autònoma de Barcelona (UAB), Bellaterra 08193, Spain

Clinical Biochemistry Service, Vall d’Hebron University Hospital, Barcelona 08035, Spain

Ikerbasque, Basque Foundation for Science, Bilbao 48009, Spain

Funding

HORIZON EUROPE European Research Council · Consell Catal? de Recerca i Innovaci? · Ministerio de Ciencia e Innovaci?n · H2020 European Research Council

References (69)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1016/j.ccr.2007.01.01310.1016/j.ccr.2007.01.013 ↗
3. 10.1038/415530a10.1038/415530a ↗
4. 10.1158/1078-0432.CCR-06-304510.1158/1078-0432.CCR-06-3045 ↗
5. 10.1016/j.cell.2018.03.04110.1016/j.cell.2018.03.041 ↗
6. 10.3389/fphar.2020.59996510.3389/fphar.2020.599965 ↗
7. 10.1016/j.semcancer.2021.06.01510.1016/j.semcancer.2021.06.015 ↗
8. 10.1016/j.biocel.2018.12.00110.1016/j.biocel.2018.12.001 ↗
9. 10.1073/pnas.100673210710.1073/pnas.1006732107 ↗
10. 10.1186/bcr211110.1186/bcr2111 ↗
11. 10.1016/j.stem.2018.11.01710.1016/j.stem.2018.11.017 ↗
12. 10.1172/JCI4501410.1172/JCI45014 ↗
13. 10.3390/cells1205072010.3390/cells12050720 ↗
14. 10.3389/fmolb.2020.0003310.3389/fmolb.2020.00033 ↗
15. 10.1158/2159-8290.CD-RW2022-01410.1158/2159-8290.CD-RW2022-014 ↗
16. 10.1016/j.cub.2020.06.08110.1016/j.cub.2020.06.081 ↗
17. 10.1158/0008-5472.CAN-12-012210.1158/0008-5472.CAN-12-0122 ↗
18. 10.1016/j.ccr.2004.06.01010.1016/j.ccr.2004.06.010 ↗
19. 10.1002/adhm.20220260910.1002/adhm.202202609 ↗
20. 10.1038/s41698-020-0121-210.1038/s41698-020-0121-2 ↗
21. 10.1021/acsbiomaterials.6b0024610.1021/acsbiomaterials.6b00246 ↗
22. 10.1016/j.actbio.2019.01.00910.1016/j.actbio.2019.01.009 ↗
23. 10.3390/ijms2307343210.3390/ijms23073432 ↗
24. 10.1038/nbt.295810.1038/nbt.2958 ↗
25. 10.1021/acsbiomaterials.8b0127710.1021/acsbiomaterials.8b01277 ↗
26. 10.1016/j.tranon.2021.10101510.1016/j.tranon.2021.101015 ↗
27. 10.1002/anbr.20200009710.1002/anbr.202000097 ↗
28. 10.1002/adhm.20190179810.1002/adhm.201901798 ↗
29. 10.1002/advs.20210346910.1002/advs.202103469 ↗
30. 10.1002/adma.20200547610.1002/adma.202005476 ↗
31. 10.1002/adhm.20200073410.1002/adhm.202000734 ↗
32. 10.7150/thno.8178510.7150/thno.81785 ↗
33. 10.18063/ijb.v9i1.63010.18063/ijb.v9i1.630 ↗
34. 10.1016/j.mtbio.2023.10082610.1016/j.mtbio.2023.100826 ↗
35. 10.1002/adfm.20190965510.1002/adfm.201909655 ↗
36. 10.1021/acsami.2c0261510.1021/acsami.2c02615 ↗
37. 10.1021/acsami.0c0322210.1021/acsami.0c03222 ↗
38. 10.1021/acsami.2c1854510.1021/acsami.2c18545 ↗
39. 10.1021/acs.jpcc.3c0371310.1021/acs.jpcc.3c03713 ↗
40. 10.1021/acs.chemmater.6b0334910.1021/acs.chemmater.6b03349 ↗
41. 10.1016/j.nano.2015.07.00910.1016/j.nano.2015.07.009 ↗
42. 10.3390/ijms23191176010.3390/ijms231911760 ↗
43. 10.3390/cancers1108105810.3390/cancers11081058 ↗
44. 10.1002/ijc.3444710.1002/ijc.34447 ↗
45. 10.1002/cac2.1229110.1002/cac2.12291 ↗
46. 10.1038/bjc.2013.76810.1038/bjc.2013.768 ↗
47. 10.1098/rsos.22027010.1098/rsos.220270 ↗
48. 10.1038/s41536-021-00193-510.1038/s41536-021-00193-5 ↗
49. 10.1016/j.mattod.2015.01.01910.1016/j.mattod.2015.01.019 ↗
50. 10.1016/j.biomaterials.2018.02.03010.1016/j.biomaterials.2018.02.030 ↗
51. 10.3389/fphar.2020.0090410.3389/fphar.2020.00904 ↗
52. 10.1038/nrclinonc.2017.4410.1038/nrclinonc.2017.44 ↗
53. 10.1186/bcr343610.1186/bcr3436 ↗
54. 10.1172/JCI3939710.1172/JCI39397 ↗
55. 10.17219/acem/6212010.17219/acem/62120 ↗
56. 10.1172/JCI14529610.1172/JCI145296 ↗
57. 10.3892/or.2020.777010.3892/or.2020.7770 ↗
58. 10.1038/s41419-023-05576-810.1038/s41419-023-05576-8 ↗
59. 10.7150/ijbs.2284910.7150/ijbs.22849 ↗
60. 10.4048/jbc.2020.23.e1710.4048/jbc.2020.23.e17 ↗
61. 10.1186/s40169-018-0205-610.1186/s40169-018-0205-6 ↗
62. 10.1172/JCI5709910.1172/JCI57099 ↗
63. 10.1038/s41416-020-01161-410.1038/s41416-020-01161-4 ↗
64. 10.1016/j.semcancer.2017.02.01110.1016/j.semcancer.2017.02.011 ↗
65. 10.1016/j.tibtech.2012.12.00310.1016/j.tibtech.2012.12.003 ↗
66. 10.1016/j.molcel.2015.10.03110.1016/j.molcel.2015.10.031 ↗
67. 10.1158/1078-0432.CCR-16-274810.1158/1078-0432.CCR-16-2748 ↗
68. 10.18632/oncotarget.623410.18632/oncotarget.6234 ↗
69. 10.3389/fonc.2019.0004010.3389/fonc.2019.00040 ↗